Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction analysis of lenvatinib with VEGFR2 and X-ray analysis of the crystal structure of VEGFR2-lenvatinib complexes. Kinetic analysis revealed that lenvatinib had a rapid association rate constant and a relatively slow dissociation rate constant in complex with VEGFR2. Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [20]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
CH/? hydrogen bonds in crystals
Nishio, M. (2004) · CrystEngComm · doi:10.1039/b313104a · Cited by 1,422
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Research works printed but not linked: 1
- Schlumberger M., 2014, ASCO Meet. Abstr., 32, LBA6008
Cited by
Items 101–200 of 306
Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
Zhu, Y., & Hu, X. (2022) · Molecules · doi:10.3390/molecules27207124 · Cited by 25
“57 Å resolution X-ray crystal structure of lenvatinib bound VEGFR 2 (PDB ID: 3WZD [69]).”
BackgroundA review of 2014 cancer drug approvals, with a look at 2015 and beyond.
Butler, T. W., Maravent, S., Boisselle, J., Valdés, J. A. M., & Fellner, C. (2015) · Europe PMC (PubMed Central) · Cited by 25
El‐Damasy, A. K., Cho, N., Nam, G., Pae, A. N., & Keum, G. (2016) · ChemMedChem · doi:10.1002/cmdc.201600224 · Cited by 25
Yu, J. X., Craig, A. J., Duffy, M. E., Villacorta-Martín, C., Miguela, V., de Galarreta, M. R., Scopton, A. P., Silber, L., Maldonado, A. Y., Rialdi, A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0571 · Cited by 24
“While the mode of engagement by sorafenib, regorafenib, cabozantinib, and lenvatinib (17) is similar, the precise kinase targets for these compounds vary (14, 18) and likely contribute to the differing biological efficacy for each drug.”
BackgroundFaydy, M. E., Dahaieh, N., Ounine, K., Lakhrissi, B., Warad, I., Tüzün, B., & Zarrouk, A. M. (2021) · Arabian Journal for Science and Engineering · doi:10.1007/s13369-021-05749-7 · Cited by 23
El-Khouly, O. A., Henen, M. A., El‐Sayed, M. A. ‐., & El‐Messery, S. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-21277-2 · Cited by 23
Naufal, M., Hermawati, E., Syah, Y. M., Hidayat, A. T., Hidayat, I. W., & Anshori, J. A. (2024) · ACS Omega · doi:10.1021/acsomega.3c04749 · Cited by 26
Khaled, N. B., Møller, M., Jochheim, L. S., Leyh, C., Ehmer, U., Böttcher, K., Pinter, M., Balcar, L., Scheiner, B., Weich, A., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101065 · Cited by 28
Adachi, Y., Matsuki, M., Watanabe, H., Takase, K., Kodama, K., Matsui, J., Funahashi, Y., & Nomoto, K. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1601209 · Cited by 24
“Given the high affinity of lenvatinib for VEGFR2 via a binding mode (type V) that is distinct among other VEGFR tyrosine kinase inhibitors (17), the association between VEGF expression level and the antitumor activity of lenvatinib warrants investigation.”
BackgroundSelf-citationThe VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance
Grillo, E., Romani, C., Ettorre, V. M., Santin, A. D., & Mitola, S. M. F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189374 · Cited by 27
Rampogu, S. D., Baek, A., Park, C., Son, M., Parate, S., Saravanan, P., Park, Y., Shaik, B., Kim, J. H., Park, S. J., et al. (2019) · Cells · doi:10.3390/cells8030269 · Cited by 24
Eze, C. C., Ezeokonkwo, M. A., Ugwu, D. I., Eze, F. U., Onyeyilim, E. L., Attah, S. I., & Okonkwo, V. I. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220318090147 · Cited by 22
Xue, M., Wu, Y., Zhu, B., Zou, X., Fan, W., & Li, J. (2021) · PubMed Central · Cited by 23
Kashyap, K., & Kakkar, R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1567388 · Cited by 20
Adel, M., & Abouzid, K. A. M. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106006 · Cited by 20
Șandor, A., Fizeșan, I., Ionuţ, I. A., Marc, G., Moldovan, C., Oniga, I., Pîrnău, A., Vlase, L., Petru, A.-E., Macasoi, I. G., et al. (2024) · Biomolecules · doi:10.3390/biom14020218 · Cited by 20
Munni, Y. A., Ali, M. C., Selsi, N. J., Sultana, M., Hossen, M., Bipasha, T. H., Rahman, M., Uddin, M. N., Hosen, S. M. Z., & Dash, R. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107414 · Cited by 20
Elgawish, M. S., Nafie, M. S., Yassen, A. S. A., Yamada, K., & Ghareb, N. (2022) · New Journal of Chemistry · doi:10.1039/d1nj05655g · Cited by 21
Liu, M., Meng, X., Mao, Y., Li, H., & Liu, J. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01554 · Cited by 21
Jaballah, M. Y., Serya, R. A. T., Saad, N., Khojah, S. M., Ahmed, M., Barakat, K., & Abouzid, K. A. M. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1651723 · Cited by 19
Chen, Y.-X., Zhang, J.-X., Zhou, C., Liu, J., Liu, S., Shi, H., & Zu, Q. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s373250 · Cited by 23
“Compared with sorafenib, lenvatinib has higher selective inhibition of VEGF receptors.(14) Moreover, lenvatinib inhibits FGF receptors and rearranged during transfection (RET), thereby suppressing tumor angiogenesis and tumor cell proliferation.”
BackgroundAl-Wahaibi, L. H., Mohammed, A. F., Abdelrahman, M. H., Trembleau, L., & Youssif, B. G. M. (2023) · Pharmaceuticals · doi:10.3390/ph16071039 · Cited by 18
“VEGFR-2 is one of these protein kinases that are involved in endothelial cell survival/proliferation and cancer development [70,71].”
BackgroundSchmidt, D., Scharf, M. M., Sydow, D., Aßmann, E., Martí-Solano, M., Keul, M., Volkamer, A., & Kolb, P. (2021) · Molecules · doi:10.3390/molecules26030629 · Cited by 18
“Finally, the crystal structures (PDB IDs given in parentheses) for EGFR (1XKK [30], 3POZ [31]), ErbB2 (3PP0 [31], 3RCD [32]), BRAF (1UWH [33], 3PPK [34]), PI3K (4JPS [35]) and VEGFR2 (2P2H, 3WZD [36]) were downloaded from the PDB (a summary of structural details is presented in Table 6).”
MethodWang, Q., Liu, F., Wang, B., Zou, F., Qi, Z., Chen, C., Yu, K., Hu, C., Qi, S., Wang, W., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01290 · Cited by 18
Mashelkar, K. K., Byun, W. S., Ko, H., Sung, K., Tripathi, S., An, S., Yum, Y. A., Kwon, J. Y., Kim, M., Kim, G., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14121290 · Cited by 18
Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update
Naik, R. R., & Shakya, A. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1064472 · Cited by 17
“Lenvatinib is a TKI that inhibits VEGFR and various other FGFRs, such as FGFR1, FGFR2, FGFR3, FGFR4, PDGFRs, RET, and c-Kit (Okamoto et al., 2015; Kannaiyan and Mahadevan, 2018).”
BackgroundNeoadjuvant Lenvatinib in Advanced Unresectable Medullary Thyroid Carcinoma: A Case Report
Golingan, H., Hunis, B., Golding, A. C., Bimston, D. N., & Harrell, R. M. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0365 · Cited by 17
“Lenvatinib is an oral multikinase inhibitor of VEGFR 1 to 3, fibroblast growth factor receptor 1 to 4, plateletderived growth factor receptor alpha, the ret protooncogene (RET), and the KIT proto-oncogene (12-14).”
BackgroundWang, H., Zuo, J., Zha, L., Jiang, X., Wu, C., Yang, Y.-A., Tang, W., & Shi, T. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104755 · Cited by 18
Lenvatinib: A narrative drug review
Goel, A., & Singla, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_151_21 · Cited by 19
Önem, E., Tüzün, B., & Akkoç, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1890222 · Cited by 17
Lenvatinib for the treatment of kidney cancer
Študentová, H., Vitásková, D., & Melichar, B. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1470506 · Cited by 16
“Lenvatinib is an oral MTKI targeting VEGFR-1–3, PDGFR-alpha, FGFR-1–4, RET, and KIT[28,29,36].”
BackgroundInfluentialZheng, Z., Hou, B., Cheng, X., Liu, W., Huang, X., Bao, Y., Wang, T., Wang, Z., & Hao, H. (2020) · Acta Crystallographica Section B Structural Science Crystal Engineering and Materials · doi:10.1107/s2052520620003935 · Cited by 16
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer
Fogli, S., Gianfilippo, G., Cucchiara, F., Re, M. D., Valerio, L., Elisei, R., & Danesi, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103366 · Cited by 16
Hua, X., Yin, Z., Liang, J., Chen, W., & Gong, H. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002668 · Cited by 16
“Secondly, as a VEGF TKI, Lenvatinib exhibits a faster binding and relatively slower dissociation compared to other TKIs [33].”
BackgroundRossari, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Yoo, C., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34799 · Cited by 16
Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes
Zhang, J., Zhang, L., Wang, Y., & Zhao, G. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2961-6 · Cited by 17
Kato, T., Mizuno, R., & Miyake, H. (2024) · International Journal of Urology · doi:10.1111/iju.15409 · Cited by 15
Mohamed, M. F., Saddiq, A. A., & Abdelhamid, I. A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104195 · Cited by 15
Li, C., Cui, Y., Ren, J., Zou, J., Kuang, W., Sun, X., Hu, X. Y., Yan, Y., & Ling, X. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c03566 · Cited by 16
Hafez, H. N., Abbas, H. S., & El-Sayed, A. F. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138349 · Cited by 14
Srour, A. M., Nossier, E. S., Altwaijry, N., Mousa, S., Awad, H. M., & Elzahabi, H. S. A. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2431475 · Cited by 14
Galati, G., Vainieri, A. F. M., Fulgenzi, C. A. M., Donato, S. D., Silletta, M., Gallo, P., Onorato, A., Gentilucci, U. V., & Picardi, A. (2020) · Current Drug Metabolism · doi:10.2174/1389200221999200918141239 · Cited by 14
Verburg, F. A., Amthauer, H., Binse, I., Brink, I., Buck, A. K., Darr, A., Dierks, C., Koch, C., König, U. M., Kreissl, M. C., et al. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1380-4154 · Cited by 14
Yalazan, H., Tüzün, B., Akkaya, D., Barut, B., Kantekın, H., & Yıldırmış, S. (2022) · Applied Organometallic Chemistry · doi:10.1002/aoc.6696 · Cited by 13
Abudayah, A., Daoud, S., Al-Sha’er, M. A., & Taha, M. O. (2022) · Molecular Informatics · doi:10.1002/minf.202200049 · Cited by 13
Wang, Z., Sun, L., Xu, Y., Huang, J., Yang, F., & Chang, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05893-2 · Cited by 12
“Remarkably, the RMSD value of the redocked pose was 0.28 Å, falling below the threshold of 1.90 Å, thus demonstrating the precision of our docking methodology and parameters [48].”
Influential1,3,4‐Thiadiazole Derivatives as VEGFR‐2 Inhibitors and Its Molecular Insight for Cancer Therapy
Gawande, P., Matore, B. W., Murmu, A., Kumar, A., Jana, S., Roy, P. P., & Singh, J. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202501361 · Cited by 14
Mavrova, A. T., & Yancheva, D. Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108920 · Cited by 13
To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
Basu, D., Pal, R., Sarkar, M., Barma, S., Halder, S., Roy, H., Nandi, S., & Samadder, A. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266261150231110053650 · Cited by 13
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead
Mologni, L., Via, M. D., Chilin, A., Palumbo, M., & Marzaro, G. (2017) · ChemMedChem · doi:10.1002/cmdc.201700243 · Cited by 12
de la Fouchardière, C., Ghuzlan, A. A., Bardet, S., Borget, I., Borson‐Chazot, F., Cao, C. D., Godbert, Y., Leenhardt, L., Zerdoud, S., & Leboulleux, S. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.04.012 · Cited by 12
Matsui, J. (2016) · Global Journal of Cancer Therapy · doi:10.17352/gjct.000009 · Cited by 13
“Lenvatinib is an orally administered multiple receptor tyrosine kinase inhibitor with a novel binding mode that selectively targets the kinase activities of VEGFRs (VEGFR1-3) and FGFRs (FGFR1-4) in addition to other pro-angiogenic and oncogenic pathway-related RTKs including PDGFRα, KIT and RET [18-23].”
BackgroundSelf-citationEl‐Nagar, M. K. S., Shahin, M. I., El‐Behairy, M. F., Taher, E. S., El‐Badawy, M. F., Sharaky, M. M., Ella, D. A. A. E., Abouzid, K. A. M., & Adel, M. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00481g · Cited by 11
Gu, Y. J., Tang, T., Qiu, M., Wang, H., Ampofo, E., Menger, M. D., & Laschke, M. W. (2025) · Angiogenesis · doi:10.1007/s10456-024-09965-1 · Cited by 11
“2a), enabling their binding to the ATP binding site of VEGFR2 [35, 36].”
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
Lisi, D. D., Giorgi, U. D., Lolli, C., Schepisi, G., Conteduca, V., Menna, C., Tonini, G., Santini, D., & Farolfi, A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1455826 · Cited by 12
Halogenated Flavonoid Derivatives Display Antiangiogenic Activity
Khater, M. A., Watson, K. A., Boateng, S. Y., Greco, F., & Osborn, H. M. I. (2022) · Molecules · doi:10.3390/molecules27154757 · Cited by 11
Fukuhara, T., Donishi, R., Koyama, S., Miyake, N., Matsuda, E., Fujiwara, K., Kitano, H., & Takeuchi, H. (2017) · Case Reports in Oncology · doi:10.1159/000457831 · Cited by 10
Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective
Pitoia, F., Scheffel, R. S., Califano, I., Gauna, A., Tala, H., Vaisman, F., Román-Gonzaléz, A., Hoff, A. O., & Maia, A. L. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09818-0 · Cited by 11
“Both selectively inhibit vascular endothelial growth factor receptors 1–3, platelet-derived growth factor receptor α, and RET proto-oncogene, albeit via distinct binding modes [70].”
Kudo, M., Finn, R. S., Ikeda, M., Sung, M. W., Baron, A. D., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., Pracht, M., et al. (2023) · Liver Cancer · doi:10.1159/000535154 · Cited by 10
Kawano, S., Kawada, M. I., Fukushima, S., Arai, Y., SHIBATA, T., & Miyano, S. W. (2024) · Anticancer Research · doi:10.21873/anticanres.17046 · Cited by 10
“(VEGFR2) complex with lenvatinib and a kinetic interaction analysis indicated that lenvatinib binds in a different and distinct mode to VEGFR2 compared to other approved VEGFR2 kinase inhibitors (32).”
BackgroundDesign and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors
Elgammal, W. E., Elkady, H., Dahab, M. A., Mahdy, H. A., Hagras, M., Nofal, A., Alsfouk, B. A. A., Elkaeed, E. B., Eissa, I. H., & Metwaly, A. M. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2485863 · Cited by 10
Aref, M. M. A., Abdallah, A. E., Dahab, M. A., Mohamed, A. A., Çelik, İ., Bawazir, W. A., Mansoure, A. A., Alnami, A. T., Abdelhamed, M. N., & El‐Zahabi, M. A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118187 · Cited by 12
Liu, J., Yan, S., Zhang, G., Yang, L., Wei, S., & Yi, P. (2023) · Oncology Letters · doi:10.3892/ol.2023.14094 · Cited by 9
Gangapuram, M., Eyunni, S., Zhang, W., & Redda, K. K. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210112122913 · Cited by 9
“Molecular Docking Studies The crystal structures of Human KRas receptor protein (PDB: 4EPX) [26] and VEGF2 Receptor Protein (PDB: 3WZD) [27], whose coordinates were obtained from RCSB Protein Data Bank were used.”
Shevchenko, E., & Pantsar, T. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210837 · Cited by 9
Shraim, A. S., Hunaiti, A. A., Awidi, A., Alshaer, W., Ababneh, N. A., Abu‐Irmaileh, B., Odeh, F., & Ismail, S. I. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00868 · Cited by 9
Network pharmacology reveals the potential of Dolastatin 16 as a diabetic wound healing agent
Luthfiana, D., & Utomo, D. H. (2023) · In Silico Pharmacology · doi:10.1007/s40203-023-00161-5 · Cited by 10
Yamazaki, H., Yokose, T., Hayashi, H., Iwasaki, H., Osanai, S., Suganuma, N., Nakayama, H., Masudo, K., Rino, Y., & Masuda, M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3657-x · Cited by 8
Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2
Lee, S., Wang, S., Yu, C.-L., Tai, H., Yen, J.-Y., Tuan, Y.-L., Wang, H.-H., Liu, Y.-T., Chen, S.-S., & Lee, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116454 · Cited by 8
Adashek, J. J., Breunig, J. J., Posadas, E. M., Bhowmick, N. A., Ellis, L., Freedland, S. J., Kim, H. L., Figlin, R. A., & Gong, J. (2022) · Drugs · doi:10.1007/s40265-022-01683-6 · Cited by 8
“A distinct feature of lenvatinib compared to other TKIs is that it exhibits a novel binding mechanism to VEGFR2 causing it to bind more rapidly as well as dissociate slower than sunitinib [46].”
BackgroundRongala, G., Rongala, D. S., & Rongala, A. N. (2025) · Journal of Pharmaceutical and BioTech Industry · doi:10.3390/jpbi2040019 · Cited by 7
“Type V inhibitors like Lenvatinib act as bivalent inhibitors bound to two different portions of the kinase [71].”
Abdallah, A. E., El‐Fakharany, E. M., El‐Maradny, Y. A., Çelik, İ., El‐Zahabi, M. A., Bass, A. K. A., Elkady, M. A., & Alesawy, M. S. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109792 · Cited by 7
Bansod, A. A., Gnanam, R., Nathan, B., Kandhasamy, R., Meenakshisundaram, P., & Santhanakrishnan, V. P. (2021) · 3 Biotech · doi:10.1007/s13205-021-02768-x · Cited by 7
Rahman, D. E. A., Fouad, M. A., Mohammed, E. R., El-Zoheiry, H. H., & Allam, H. A. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106678 · Cited by 9
“org/) (PDB ID: 3WZE) in pdb format [54].”
Advances in pharmacotherapeutics for hepatocellular carcinoma
Cerrito, L., Santopaolo, F., Monti, F., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1892074 · Cited by 7
“tively slower dissociation rate in complex with VEGFR2 compared to sorafenib [30].”
BackgroundLorusso, D., Danesi, R., Locati, L. D., Masi, G., Giorgi, U. D., Gadducci, A., Pignata, S., Sabbatini, R., Savarese, A., Valabrega, G., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.979519 · Cited by 7
“This interaction may contribute to prolonging the binding time compared with that of other inhibitors, such as sorafenib (11).”
BackgroundPannucci, P., Daele, M. V., Cooper, S. L., Wragg, E. S., March, J. E., Groenen, M., Hill, S. J., & Woolard, J. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.116007 · Cited by 7
Verma, P., Hassan, M. I., Singh, A. K., & Singh, I. K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04134-0 · Cited by 7
Xie, Q., Luo, M., Liu, M., Xie, Y., Li, D., Dai, H., & Chen, X. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d4cp03575e · Cited by 6
Sertraline: Theoretical Studies and a New Potentiometric PVC Membrane Sensor for its Determination
Saber, A. L., Tüzün, B., Alessa, H., & Althakafy, J. T. (2022) · Current Analytical Chemistry · doi:10.2174/1573411019666221124091744 · Cited by 6
Otani, Y., Kasai, H., & Tanigawara, Y. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12587 · Cited by 6
Șandor, A., Crișan, O., Marc, G., Fizeșan, I., Ionuţ, I. A., Moldovan, C., Stana, A., Oniga, I., Pîrnău, A., Vlase, L., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020260 · Cited by 5
Парченко, В. В., Poustforoosh, A., Karpenko, Y. V., Kyrychko, B. P., Tüzün, B., Kyrychko, E., Четвертак, Т., & Kul, B. (2025) · Turkish computational and theoretical chemistry/Turkish computational and theoretical chemistry : · doi:10.33435/tcandtc.1678153 · Cited by 5
Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties
Chu, H., Wei, Y., Zhao, H., Ye, F., Qian, X., Su, H., Sun, Y., Zhang, J., Jia, Z., Li, Z., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118227 · Cited by 5
Ji, Y., Chen, Z., Liu, Z., Man, X., Du, J., & Yu, B. (2026) · Expert Systems with Applications · doi:10.1016/j.eswa.2026.131485 · Cited by 7
Keshavarz, F., Soltanshahi, M., Ayadilord, M., Mortazavi, F. S., Shabani, M., & Jalali, S. A. (2026) · Cancer Cell International · doi:10.1186/s12935-025-04141-x · Cited by 6
“Lenvatinib’s core action as an oral multi-kinase inhibitor targets angiogenic receptor tyrosine kinases, including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, thereby disrupting tumor vascularization and growth [205, 206].”
Shoji, T., Takeuchi, M., Uda, M., Ariga, Y., Yamazaki, A., Sekiguchi, R., & Ito, S. (2023) · Molecules · doi:10.3390/molecules28155785 · Cited by 5
“In recent years, quinoline derivatives such as bosutinib [13], lenvatinib [14], and cabozantinib [15] have been employed clinically as anticancer agents (Figure 1).”
BackgroundWang, Y., Nan, X., Duan, Y., Wang, Q., Liang, Z., & Yin, H. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117870 · Cited by 5
Xu, L., Zeng, K., Duan, Z., Liu, J., Zeng, Y., Zhang, M., Yang, Y., Guo, Q., Jin, Y., Liu, W., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1518525 · Cited by 5
Alos, H. C., Billones, J. B., Vasquez, R. D., & Castillo, A. L. (2020) · Current Enzyme Inhibition · doi:10.2174/1573408016666200123160509 · Cited by 5
Peng, C., Rabold, K., Netea, M. G., Jaeger, M., & Netea-Maier, R. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020412 · Cited by 5
“Lenvatinib is a multitargeted kinase inhibitor with a particularly potent activity against the VEGFR2 via type V binding model [46].”
BackgroundDutta, D., Das, R., Mandal, C., & Mandal, C. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00227 · Cited by 5
Synthesis and Antitumor Activity of Sorafenib Analogs Containing a Tetrazole Moiety
Tian, Y., Yu, S., Cai, L., Gong, G., Wu, G., Qi, H., Zhao, Y., & Qin, M. (2018) · Chemical Research in Chinese Universities · doi:10.1007/s40242-018-8236-5 · Cited by 5
Monica, G. L., Bono, A., Alamia, F., Martorana, A., & Lauria, A. (2025) · ChemistryOpen · doi:10.1002/open.202400518 · Cited by 4
Aljohani, M. S., & Hu, X. (2025) · Molecules · doi:10.3390/molecules30051007 · Cited by 4
“Similarly, Figure 3b depicts the intermolecular interaction map for BAX and its inter-acting residues in MAPK14, based on the 1.90 Å resolution X-ray crystal structure (PDB ID: 3WZE) [28].”
InfluentialClinical and preclinical insights into a novel MDM2::PDGFRA fusion in recurrent glioblastoma
Beach, C. Z., Febres‐Aldana, C. A., Marti, J. L. G., Asiry, S., Wong, T., Boockvar, J. A., D’Amico, R. S., Somwar, R., Davare, M. A., & Vojnic, M. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01076-4 · Cited by 4
“Lenvatinib, a proposed Type V TKI 44 , exhibits a dual binding mode in which it occupies the ATP-binding cleft (DFG-in) while its cyclopropane moiety extends into the adjacent hydro-phobicbackpocket 45 ,therebycombiningfeaturesofbothTypeIandTypeII inhibitors.”
Peck‐Radosavljevic, M., Abdelgafur, A., Granito, A., Gasbarrini, A., Ma, Y. T., Mena, E., Lledó-Navarro, J. L., Presa, J., Weinmann, A., Levy, M. T., et al. (2026) · Liver Cancer · doi:10.1159/000552115 · Cited by 4
Whitely, C., Winburn, H., & Li, Y. (2024) · ChemistrySelect · doi:10.1002/slct.202304688 · Cited by 4
Tsuruoka, A., Matsui, J., Suzuki, T., Koyama, N., Watanabe, T., & Funahashi, Y. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.146.283 · Cited by 4
Self-citationO’Reilly, A., & Larkin, J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1289840 · Cited by 4
“The clinical implications of lenvatinib’s status as a type V inhibitor have yet to be revealed but these unique characteristics may contribute to lenvatinib’s potency and side-effect profile as seen in clinical trials [44].”
Background
Metadata
- Authors
- Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J.
- Affiliations
- Eisai (Japan) (JP)
- Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
- Proteros Biostructures GmbH, Planegg-Martinsried, Germany
- Eisai (United States) (US)
- Corresponding author
- Matsui, Junji
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-11-20
- Volume
- 6
- Issue
- 1
- Pages
- 89-94
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4291723
- OpenAlex
- W1976262446
- Cited by
- 285
- References
- 28
- Citations by year
- 2026: 32 · 2025: 29 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 40 · 2020: 24 · 2019: 23 · 2018: 19 · 2017: 12 · 2016: 11 · 2015: 7
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- lenvatinib, VEGFR2, multikinase inhibitor, ATP binding site, binding kinetics, crystal structure, receptor tyrosine kinase inhibition, VEGF receptor inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.